54 clinical trials found.
-
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-na ve EGFR-mutant Locally Advanced or Metastatic NSCLC
The purpose of this study is to find out whether the addition of ramucirumab to osimertinib is better at controlling EGFR lung cancer than just ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
The Selective Personalized Radio-Immunotherapy for locally advanced NSCLC Trial (SPRINT)
The purpose of this study is to determine if, for locally advanced non-small cell lung cancer patients whose tumors have high levels of PD-L1 (a ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 1/2 Open-Label Dose-Escalation Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors
The purpose of this research study is to learn about the effects of the study drug, NC318, when given as an investigational combination treatment for ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC) Locally Advanced or Metastatic with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)
If you have been diagnosed with Non-Small Cell Lung Cancer that has tested positive for the presence of EGFR or HER2 Exon 20 Insertion (lung ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
The main goal of this phase III study is to evaluate whether adjuvant therapy with crizotinib (an ATP blocker of several tyrosine kinases) will result ...
Phase
Interventional
TRIAL ROLE: Principal Investigator
-
First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
The purpose of the study is to determine the safety of GEN1046 in patients with malignant solid tumors. GEN1046 is investigational drug in this study ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 1-2 First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Lymphomas.
The study is being done to look at: • The possible side effects, safety and tolerability of CX-2029 • The highest dose of CX-2029 that can be ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
MULTICENTER PHASE II NEOADJUVANT AND ADJUVANT STUDY OF ALECTINIB ENTRECTINIB OR VEMURAFENIB PLUS COBIMETINIB IN PATIENTS WITH STAGES I-III NON-SMALL CELL LUNG CANCER WITH ALK ROS1 NTRK OR BRAF V600E MOLECULAR ALTERATIONS
The purpose of the trial is to determine the efficacy and safety of drugs in patients with untreated non-small cell lung cancer (NSCLC) tumors. In ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
Phase 2 Multicenter Randomized Study of DS-1062a in Advanced or Metastatic NSCLC w/ Actionable Genomic Alterations and Previously Treated with Kinase Inhibitor Therapy and Platinum-based Chemotherapy w/ or w/o Prior Immunotherapy
The purpose of the study is to evaluate the efficacy and safety of DS-1062a in subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
Randomized Phase II Trial of Topotecan plus M6620 (VX-970) vs. Topotecan alone in Patients with Relapsed Small-Cell Lung Cancer
The purpose of the study is to determine the efficacy of topotecan in combination with M6620 or topotecan alone for Relapsed Small-Cell Lung Cancer (SCLC ...Phase
Interventional
TRIAL ROLE: Principal Investigator
